Putting a Kink in HIV-1 Particle Infectivity: Rocaglamide Inhibits HIV-1 Replication by Altering Gag-Genomic RNA Interaction

Our examination of RNA helicases for effects on HIV-1 protein production and particle assembly identified Rocaglamide (RocA), a known modulator of eIF4A1 function, as an inhibitor of HIV-1 replication in primary CD4<sup>+</sup> T cells and three cell systems. HIV-1 attenuation by low-nM...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul Rosenfeld, Gatikrushna Singh, Amanda Paz Herrera, Juan Ji, Bradley Seufzer, Xiao Heng, Kathleen Boris-Lawrie, Alan Cochrane
Format: Article
Language:English
Published: MDPI AG 2024-09-01
Series:Viruses
Subjects:
Online Access:https://www.mdpi.com/1999-4915/16/9/1506
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850258249996042240
author Paul Rosenfeld
Gatikrushna Singh
Amanda Paz Herrera
Juan Ji
Bradley Seufzer
Xiao Heng
Kathleen Boris-Lawrie
Alan Cochrane
author_facet Paul Rosenfeld
Gatikrushna Singh
Amanda Paz Herrera
Juan Ji
Bradley Seufzer
Xiao Heng
Kathleen Boris-Lawrie
Alan Cochrane
author_sort Paul Rosenfeld
collection DOAJ
description Our examination of RNA helicases for effects on HIV-1 protein production and particle assembly identified Rocaglamide (RocA), a known modulator of eIF4A1 function, as an inhibitor of HIV-1 replication in primary CD4<sup>+</sup> T cells and three cell systems. HIV-1 attenuation by low-nM RocA doses was associated with reduced viral particle formation without a marked decrease in Gag production. Rather, the co-localization of Gag and HIV-1 genomic RNA (gRNA) assemblies was impaired by RocA treatment in a reversible fashion. Ribonucleoprotein (RNP) immunoprecipitation studies recapitulated the loss of Gag-gRNA assemblies upon RocA treatment. Parallel biophysical studies determined that neither RocA nor eIF4A1 independently affected the ability of Gag to interact with viral RNA, but together, they distorted the structure of the HIV-1 RNP visualized by electron microscopy. Taken together, several lines of evidence indicate that RocA induces stable binding of eIF4A1 onto the viral RNA genome in a manner that interferes with the ordered assembly of Gag along Gag-gRNA assemblies required to generate infectious virions.
format Article
id doaj-art-c1097bdb587d4cc7a05a32e1f45331f9
institution OA Journals
issn 1999-4915
language English
publishDate 2024-09-01
publisher MDPI AG
record_format Article
series Viruses
spelling doaj-art-c1097bdb587d4cc7a05a32e1f45331f92025-08-20T01:56:13ZengMDPI AGViruses1999-49152024-09-01169150610.3390/v16091506Putting a Kink in HIV-1 Particle Infectivity: Rocaglamide Inhibits HIV-1 Replication by Altering Gag-Genomic RNA InteractionPaul Rosenfeld0Gatikrushna Singh1Amanda Paz Herrera2Juan Ji3Bradley Seufzer4Xiao Heng5Kathleen Boris-Lawrie6Alan Cochrane7Institute of Medical Sciences, University of Toronto, Toronto, ON M5S 1A8, CanadaDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN 55108, USADepartment of Biochemistry, University of Missouri, Columbia, MO 65211, USADepartment of Biochemistry, University of Missouri, Columbia, MO 65211, USADepartment of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN 55108, USADepartment of Biochemistry, University of Missouri, Columbia, MO 65211, USADepartment of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN 55108, USAInstitute of Medical Sciences, University of Toronto, Toronto, ON M5S 1A8, CanadaOur examination of RNA helicases for effects on HIV-1 protein production and particle assembly identified Rocaglamide (RocA), a known modulator of eIF4A1 function, as an inhibitor of HIV-1 replication in primary CD4<sup>+</sup> T cells and three cell systems. HIV-1 attenuation by low-nM RocA doses was associated with reduced viral particle formation without a marked decrease in Gag production. Rather, the co-localization of Gag and HIV-1 genomic RNA (gRNA) assemblies was impaired by RocA treatment in a reversible fashion. Ribonucleoprotein (RNP) immunoprecipitation studies recapitulated the loss of Gag-gRNA assemblies upon RocA treatment. Parallel biophysical studies determined that neither RocA nor eIF4A1 independently affected the ability of Gag to interact with viral RNA, but together, they distorted the structure of the HIV-1 RNP visualized by electron microscopy. Taken together, several lines of evidence indicate that RocA induces stable binding of eIF4A1 onto the viral RNA genome in a manner that interferes with the ordered assembly of Gag along Gag-gRNA assemblies required to generate infectious virions.https://www.mdpi.com/1999-4915/16/9/1506ribonucleoprotein assemblyeIF4A1guanosine-adenosine motifRNA structure
spellingShingle Paul Rosenfeld
Gatikrushna Singh
Amanda Paz Herrera
Juan Ji
Bradley Seufzer
Xiao Heng
Kathleen Boris-Lawrie
Alan Cochrane
Putting a Kink in HIV-1 Particle Infectivity: Rocaglamide Inhibits HIV-1 Replication by Altering Gag-Genomic RNA Interaction
Viruses
ribonucleoprotein assembly
eIF4A1
guanosine-adenosine motif
RNA structure
title Putting a Kink in HIV-1 Particle Infectivity: Rocaglamide Inhibits HIV-1 Replication by Altering Gag-Genomic RNA Interaction
title_full Putting a Kink in HIV-1 Particle Infectivity: Rocaglamide Inhibits HIV-1 Replication by Altering Gag-Genomic RNA Interaction
title_fullStr Putting a Kink in HIV-1 Particle Infectivity: Rocaglamide Inhibits HIV-1 Replication by Altering Gag-Genomic RNA Interaction
title_full_unstemmed Putting a Kink in HIV-1 Particle Infectivity: Rocaglamide Inhibits HIV-1 Replication by Altering Gag-Genomic RNA Interaction
title_short Putting a Kink in HIV-1 Particle Infectivity: Rocaglamide Inhibits HIV-1 Replication by Altering Gag-Genomic RNA Interaction
title_sort putting a kink in hiv 1 particle infectivity rocaglamide inhibits hiv 1 replication by altering gag genomic rna interaction
topic ribonucleoprotein assembly
eIF4A1
guanosine-adenosine motif
RNA structure
url https://www.mdpi.com/1999-4915/16/9/1506
work_keys_str_mv AT paulrosenfeld puttingakinkinhiv1particleinfectivityrocaglamideinhibitshiv1replicationbyalteringgaggenomicrnainteraction
AT gatikrushnasingh puttingakinkinhiv1particleinfectivityrocaglamideinhibitshiv1replicationbyalteringgaggenomicrnainteraction
AT amandapazherrera puttingakinkinhiv1particleinfectivityrocaglamideinhibitshiv1replicationbyalteringgaggenomicrnainteraction
AT juanji puttingakinkinhiv1particleinfectivityrocaglamideinhibitshiv1replicationbyalteringgaggenomicrnainteraction
AT bradleyseufzer puttingakinkinhiv1particleinfectivityrocaglamideinhibitshiv1replicationbyalteringgaggenomicrnainteraction
AT xiaoheng puttingakinkinhiv1particleinfectivityrocaglamideinhibitshiv1replicationbyalteringgaggenomicrnainteraction
AT kathleenborislawrie puttingakinkinhiv1particleinfectivityrocaglamideinhibitshiv1replicationbyalteringgaggenomicrnainteraction
AT alancochrane puttingakinkinhiv1particleinfectivityrocaglamideinhibitshiv1replicationbyalteringgaggenomicrnainteraction